Incyclix Bio
PrivateLast Round
Series B
Extension
Apr 8, 2026
Total Funding Raised
$16.25M
Company Overview
Incyclix Bio is a biotechnology company focused on developing small molecule inhibitors of cyclin-dependent kinases (CDKs) to treat patients with advanced and resistant cancers.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Incyclix Bio Comps
Public and private peers based on sector, stage, and business model.
Incyclix Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 8, 2026 | ||||
| Series B Extension | Aug 25, 2025 |
Incyclix Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B Extension |
| Boxer Capital | Series B Extension |
| Hatteras Venture Partners | Series B Extension |
| Eshelman Ventures | Series B Extension |
| Cape Fear BioCapital | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 8, 2026
$5M raised in Series B Extension round.
Incyclix Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Incyclix Bio's valuation, stock price, and market status.
